Evidence map›Paper›PMID 42438169›Full record

Trial reportJournal of gastroenterology and hepatology2026

High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding: A Single-Blinded Multicenter RCT.

Kanteera Sriyudthsak, Nutbordee Nalinthassanai, Bunyos Sriapiraksa, Pakkapon Rattanachaisit, Tanisa Patcharatrakul, Rapat Pittayanon

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04394663 (High Dose Oral Omeprazole Versus Standard Continuous Intravenous Pantoprazole in Patient With Peptic Ulcer Bleeding and Undergo Successful Therapeutic Endoscopy; Non-inferiority Randomized Controlled Trial), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04394663 narecruitingnot on this map

High Dose Oral Omeprazole Versus Standard Continuous Intravenous Pantoprazole in Patient With Peptic Ulcer Bleeding and Undergo Successful Therapeutic Endoscopy; Non-inferiority Randomized Controlled Trial

TypeinterventionalSponsorKing Chulalongkorn Memorial HospitalRan2020 to 2025Enrolled128ConditionsGI BleedingArmsHigh-dose oral omeprazole, Standard IV PPI
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kanteera SriyudthsakDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross, Bangkok, Thailand.ORCID https://orcid.org/0009-0003-5266-4386
Nutbordee NalinthassanaiDivision of Gastroenterology, Department of Medicine, Surin Hospital, Surin, Thailand.
Bunyos SriapiraksaDepartment of Medicine, Surin Hospital, Surin, Thailand.
Pakkapon RattanachaisitDepartment of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Tanisa PatcharatrakulDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross, Bangkok, Thailand.
Rapat PittayanonDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross, Bangkok, Thailand.

Funding

The Gastroenterological Association of Thailand (GAT)
6 · The paper itself

Abstract

BACKGROUND AND

aimThe efficacy of high-dose oral omeprazole in peptic ulcer bleeding after successful therapeutic hemostatic endoscopy has not been well established. This study aimed to compare the efficacy of high-dose oral omeprazole versus continuous intravenous (IV) pantoprazole in rebleeding and percent time of gastric pH above 6.

methodsEligible patients were randomized with 1:1 concealed allocation to 40-mg oral omeprazole twice daily or IV pantoprazole 8 mg/h for 72 h after index gastroscopy. Gastric pH was measured for 24 h during 48-72 h after starting the assigned medication. Rebleeding at 72 h and 30 days, as well as 24-h gastric pH, were assessed.

resultsA total of 124 patients were analyzed. Seventy-two-hour rebleeding occurred in 1.6% (1/61) of the oral omeprazole group and 4.8% (3/63) of the IV pantoprazole group requiring endoscopic hemostasis (risk difference [RD] -3.1%, 95% CI -11.6% to 4.6%). Rebleeding within 30 days also showed no difference between groups (3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%). Gastric pH monitoring was completed in 48% (29/61) of the oral group and 41% (26/63) of the IV group. The median percentage of gastric pH > 6 was 56.3% (IQR 28.0%-92.0%) in the oral group and 27.3% (IQR 4.4%-77.7%) in the IV group (p = 0.064).

conclusionsHigh-dose oral omeprazole may represent a feasible alternative to continuous IV pantoprazole in terms of preventing rebleeding at 72 h and 30 days and maintaining gastric pH > 6 among patients with peptic ulcer bleeding who underwent successful therapeutic hemostatic endoscopy.

trial registrationRegistration number: NCT04394663.

Indexed as

2-PyridinylmethylsulfinylbenzimidazolesAnti-Ulcer AgentsOmeprazolePeptic Ulcer HemorrhageAdministration, IntravenousAdministration, OralAgedFemaleGastroscopyHemostasis, EndoscopicHumansHydrogen-Ion ConcentrationInfusions, IntravenousMaleMiddle AgedPantoprazole2-PyridinylmethylsulfinylbenzimidazolesAnti-Ulcer AgentsOmeprazolePantoprazolegastric pHintravenous pantoprazoleoral omeprazolepeptic ulcerrebleeding

Identifiers

PMID42438169
PMCPMC13534264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.